ASX / MEDIA ANNOUNCEMENT

18 June 2014

PROFESSOR RICHARD BOND AND DR MITCHELL GLASS
DISCUSS THE SCIENCE BEHIND INV102(nadolol) WITH BRR MEDIA

Clinical-stage drug development company Invion Limited (ASX:IVX) is delighted to invite investors to view a short video interview with Professor Richard Bond, PhD, Professor of Pharmacology, University of Houston (USA); and Invion Chief Medical Officer Dr Mitchell Glass. In this webcast, Professor Bond and Dr Glass discuss:

- The science underpinning the mechanism of action of INV102(nadolol); and
- What makes INV102 (nadolol) unique as a target treatment for chronic airway disease

Currently a Professor of Pharmacology at the University of Houston, Professor Bond is a pioneering expert on using beta-blockers as a potential treatment for chronic airway diseases. Professor Bond is highly regarded in the scientific community with published papers in top scientific journals including Nature and Science. He has received numerous awards and honours throughout his esteemed career and is the recipient of an ongoing grant from the National Institutes of Health (NIH) to study the effects of nadolol in individuals with asthma.

Dr Mitchell Glass, who leads Invion's clinical development, successfully led the development of the beta-blocker and chronic heart failure therapy carvedilol through to FDA approval, and discusses this medical, regulatory and commercial precedent to the development of INV102(nadolol).

To access the webcast, please visit this link: http://www.brr.com.au/event/124041

About Invion Limited: Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory disease and autoimmune disease. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway in the United States. INV102 (nadolol), a beta blocker (beta adrenergic inverse agonist) currently used to treat high blood pressure and migraine, is being repurposed to treat chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis. Invion is an ASX listed company (ASX:IVX)with its clinical headquarters in Delaware, USA. **FOR MORE INFORMATION CONTACT** Managing Director and CEO: Dr Greg Collier via investor@inviongroup.com